GALT (Galectin Therapeutics) Cyclically Adjusted Book per Share: $-0.37 (As of Mar. 2026)


GALT Galectin Therapeutics Inc GALT
16 GF Score
Price $4.97
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics Cyclically Adjusted Book per Share?

Galectin Therapeutics GALT 16 Cyclically Adjusted Book per Share is $-0.37 as of Mar. 2026. GuruFocus rates GALT with a GF Score™ of 16/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Galectin Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $-2.011. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-0.37 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Galectin Therapeutics was 115.40% per year. The lowest was -70.50% per year. And the median was 4.35% per year.

As of today (2026-06-30), Galectin Therapeutics's current stock price is $4.97. Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $-0.37. Galectin Therapeutics's Cyclically Adjusted PB Ratio of today is .


Galectin Therapeutics  (NAS:GALT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Galectin Therapeutics Cyclically Adjusted Book per Share Related Terms


Galectin Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics Cyclically Adjusted Book per Share Chart

Galectin Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.35 0.28 -0.01 -0.30

Galectin Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.16 -0.23 -0.30 -0.37

GALT vs PALI, IRD, VSTM: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Galectin Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Cyclically Adjusted PB Ratio falls into.


GALT
16GF Score
Galectin Therapeutics Inc GALT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galectin Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galectin Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-2.011/330.2130*330.2130
=-2.011

Current CPI (Mar. 2026) = 330.2130.

Galectin Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.237 241.018 0.325
201609 0.125 241.428 0.171
201612 0.093 241.432 0.127
201703 0.019 243.801 0.026
201706 -0.090 244.955 -0.121
201709 -0.177 246.819 -0.237
201712 -0.217 246.524 -0.291
201803 -0.168 249.554 -0.222
201806 0.020 251.989 0.026
201809 0.000 252.439 0.000
201812 -0.050 251.233 -0.066
201903 0.100 254.202 0.130
201906 0.872 256.143 1.124
201909 0.833 256.759 1.071
201912 0.762 256.974 0.979
202003 0.710 258.115 0.908
202006 0.609 257.797 0.780
202009 0.515 260.280 0.653
202012 0.384 260.474 0.487
202103 0.280 264.877 0.349
202106 0.251 271.696 0.305
202109 0.118 274.310 0.142
202112 0.006 278.802 0.007
202203 -0.142 287.504 -0.163
202206 -0.294 296.311 -0.328
202209 -0.413 296.808 -0.459
202212 -0.579 296.797 -0.644
202303 -0.753 301.836 -0.824
202306 -0.896 305.109 -0.970
202309 -0.859 307.789 -0.922
202312 -1.010 306.746 -1.087
202403 -1.180 312.332 -1.248
202406 -1.355 314.175 -1.424
202409 -1.520 315.301 -1.592
202412 -1.667 315.605 -1.744
202503 -1.809 319.799 -1.868
202506 -1.864 322.561 -1.908
202509 -1.951 324.800 -1.984
202512 -1.969 324.054 -2.006
202603 -2.011 330.213 -2.011

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-0.37 mean?
Galectin Therapeutics (GALT) has a Cyclically Adjusted Book per Share of $-0.37 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Galectin Therapeutics and its competitors.
Is Galectin Therapeutics' Cyclically Adjusted Book per Share too high?
Galectin Therapeutics' current Cyclically Adjusted Book per Share is $-0.37. Overall, Galectin Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Galectin Therapeutics' Cyclically Adjusted Book per Share compare to PALI and IRD?
Galectin Therapeutics' Cyclically Adjusted Book per Share of $-0.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Galectin Therapeutics and its competitors. Galectin Therapeutics's current Cyclically Adjusted Book per Share is $-0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galectin Therapeutics stock overvalued right now?
Galectin Therapeutics (GALT) has a current Cyclically Adjusted Book per Share of $-0.37. The current Cyclically Adjusted Book per Share is $-0.37. Galectin Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current Cyclically Adjusted Book per Share is $-0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Other Exchanges PHPN:Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
16GF Score

Get the complete analysis for GALT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97
Price